🇺🇸 FDA
Patent

US 9920297

Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene WT1

granted A61KA61K2035/11A61K2039/523

Quick answer

US patent 9920297 (Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene WT1) held by Vaximm AG expires Mon Mar 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vaximm AG
Grant date
Tue Mar 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K2035/11, A61K2039/523, A61K35/74, A61K39/00